Unlike ISM8969, Insilico’s brain-penetrant NLRP3 pipeline already with FDA IND clearance, ISM5059 features a completely different chemical core designed for peripheral-restricted potency. (IMAGE)

InSilico Medicine

Unlike ISM8969, Insilico’s brain-penetrant NLRP3 pipeline already with FDA IND clearance, ISM5059 features a completely different chemical core designed for peripheral-restricted potency.

Caption

Empowered by AI, ISM5059 demonstrated robust efficacy, excellent safety profiles in preclinical studies, and low predicted human efficacious dose, with high potential in multiple indications including autoimmune and chronic cardiometabolic diseases with no obvious CNS (central nervous system) related toxicity observed in preclinical studies.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.